EXPAND (NCT01665144) was a randomised, double-blind, phase 3 trial of siponimod in secondary progressive MS patients [1]. In this post-hoc analysis, which included the open-label extension period, baseline pNfL and pGFAP levels were determined using Single Molecule Array technology [2]. Samples from 1,369 patients were available for analysis.
In 704 patients with non-active secondary progressive MS, combined high pNfL and high pGFAP had relatively higher hazard ratios for all disability outcomes versus combined low pNfL and low pGFAP:
- time to EDSS 7.0 (HR 2.65; P=0.0014);
- time to 1-point sustained EDSS worsening (HR 1.57; P=0.0176);
- time to 3-month confirmed disability worsening (HR 1.45; P=0.0151).
Hazard ratios were also higher (range: 2.09–1.17) with a high pNfL + low pGFAP signature across all 3 outcomes (P=0.05). In 665 patients with active secondary progressive MS, the prognostic value of baseline levels of pNfL and pGFAP individually or in combination was weaker. Further analyses are ongoing, investigating other cut-offs and considering potential differential and time-dependent treatment effects.
- Kappos L, et al. Lancet. 2018;391(10127):1263-73.
- Kuhle J, et al. Plasma Neurofilament Light Chain and Glial Fibrillary Acidic Protein Levels Are Prognostic of Disability Worsening: A Biosignature That Helps Differentiating Active From Non-active SPMS. P11.001, AAN 2021 Virtual Congress, 17-22 April.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Long-term safety of atogepant as migraine prophylaxis Next Article
Dysmetabolism may drive MS progression »
« Long-term safety of atogepant as migraine prophylaxis Next Article
Dysmetabolism may drive MS progression »
Related Articles
July 30, 2019
No increased MS relapse risk postpartum
December 9, 2021
Preliminary data shows positive results of ATA188 for progressive MS
November 25, 2020
Grey matter network measures predict disability and cognition
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy